Jazz pays $145m to resolve Xyrem antitrust disputes

Jazz Pharma has offered to pay $145m to settle claims it paid to prevent generic versions of its narcolepsy drug Xyrem from reaching the US market.

FDA approves flurry of drugs ahead of holiday season

The FDA has wrapped up a series of new approvals as 2024 draws to a close, with Novo Nordisk, Pfizer, Vertex, and Hikma among the beneficiaries.

Hikma will pay $150m in US opioid settlement

Indian drugmaker Hikma has agreed in principle to a $150 million settlement to resolve lawsuits claiming that it contributed to the opioid crisis in the US, which could al

Amarin hit hard as generics loom for fish oil drug Vascepa

Chasing Mylan, Hikma tries again with rejected generic Advai...

Hikma buys potential Epipen rival from troubled Insys

UK-based pharma Hikma has snapped up assets from embattled Insys Therapeutics, including potential generics of Mylan’s Epipen allergic reaction shot and a drug to reverse the effects of opi